Grifols (GRFS)
(Delayed Data from NSDQ)
$6.27 USD
-0.12 (-1.88%)
Updated Apr 25, 2024 04:00 PM ET
After-Market: $6.27 0.00 (0.00%) 7:58 PM ET
5-Strong Sell of 5 5
C Value D Growth D Momentum C VGM
Price, Consensus and EPS Surprise
GRFS 6.27 -0.12(-1.88%)
Will GRFS be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for GRFS based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for GRFS
Is First Trust NYSE Arca Biotechnology ETF (FBT) a Strong ETF Right Now?
Should You Invest in the First Trust NYSE Arca Biotechnology ETF (FBT)?
GRFS: What are Zacks experts saying now?
Zacks Private Portfolio Services
GRFS or ZTS: Which Is the Better Value Stock Right Now?
Here's Why Grifols (GRFS) Is a Great 'Buy the Bottom' Stock Now
Is First Trust NYSE Arca Biotechnology ETF (FBT) a Strong ETF Right Now?
Other News for GRFS
Grifols SA’s Related Party Transactions: Navigating Conflicts of Interest and Investor Concerns
Grifols 2023 Annual Report on Form 20-F filed with the SEC
Grifols Celebrates 50 Years of Manufacturing Life-Changing Plasma-Derived Medicines for Patients at Flagship Site in Clayton, N.C.
Grifols reportedly looking to appoint independent directors
ATUS, ATHE and GRFS among pre-market losers